GoAI
Get started
Kato (Hong Kong) Holdings Limited logo

Kato (Hong Kong) Holdings Limited

2189.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.495

+HK$0.01 · +2.06%

Aug 24, 10:30 AM HKTData delayed

2189.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Kato (Hong Kong) Holdings Limited, an investment holding entity, primarily focuses on delivering residential and day care solutions for the elderly population across Hong Kong. The organization offers an extensive array of residential care services for seniors, encompassing lodging, expert nursing and attentive care, dietary oversight, medical assistance, physical and occupational therapy, psychological and social wellness programs, individualized attention, and recreational pursuits. Furthermore, it supplies residents with healthcare and medical goods and provides supplementary health services. Beyond its core offerings, the company also administers home care support services, engages in property investments, and furnishes property management solutions. As of March 31, 2022, it managed eight dedicated care and attention homes for seniors, providing a total of 1,129 residential spots across four distinct Hong Kong districts. These facilities operate under diverse brand names, including Fai To, Kato, Happy Luck Home, Tsuen Wan Centre, and Pine Villa. Established in 1991, the firm is based in Tuen Mun, Hong Kong, and functions as a subsidiary of Sheung Fung Limited.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
HK
CEO
Shi Shing Ngai
Listed since
Jun 13, 2019
Employees
656

Market position

Volume
16K
0.08× average
Average volume
209.55K
Average daily volume
Market cap
495M HKD
Beta
0.01
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
14.47×
P/B (TTM)
1.1×
P/S (TTM)
1.4×
Dividend yield
4.04%

Profitability & efficiency

Gross margin
38.77%
Operating margin
26.64%
Net margin
9.67%

Financial health

Debt / equity
0.6×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends102%68%33%-2%Gross margin, FY2021: 44.87%Gross margin, FY2022: 45.42%Gross margin, FY2023: 49.83%Gross margin, FY2024: 93.61%Gross margin, FY2025: 32.54%Operating margin, FY2021: 35.59%Operating margin, FY2022: 34.19%Operating margin, FY2023: 43.10%Operating margin, FY2024: 20.23%Operating margin, FY2025: 18.01%Net margin, FY2021: 30.88%Net margin, FY2022: 30.90%Net margin, FY2023: 23.66%Net margin, FY2024: 6.90%Net margin, FY2025: 9.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 44.87%. Gross margin FY2022 45.42%. Gross margin FY2023 49.83%. Gross margin FY2024 93.61%. Gross margin FY2025 32.54%. Operating margin FY2021 35.59%. Operating margin FY2022 34.19%. Operating margin FY2023 43.10%. Operating margin FY2024 20.23%. Operating margin FY2025 18.01%. Net margin FY2021 30.88%. Net margin FY2022 30.90%. Net margin FY2023 23.66%. Net margin FY2024 6.90%. Net margin FY2025 9.67%.

Income trends

Revenue

353.78M HKD+11.56%

Operating income

63.72M HKD-0.67%

Net income

34.22M HKD+56.39%
Income trends across reported periods446.94M HKD292.37M HKD137.81M HKD−16.76M HKDRevenue, FY2021: 320.34M HKDRevenue, FY2022: 408.3M HKDRevenue, FY2023: 271.33M HKDRevenue, FY2024: 317.11M HKDRevenue, FY2025: 353.78M HKDOperating income, FY2021: 114.01M HKDOperating income, FY2022: 139.61M HKDOperating income, FY2023: 116.95M HKDOperating income, FY2024: 64.15M HKDOperating income, FY2025: 63.72M HKDNet income, FY2021: 98.94M HKDNet income, FY2022: 126.15M HKDNet income, FY2023: 64.19M HKDNet income, FY2024: 21.88M HKDNet income, FY2025: 34.22M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 320.34M HKD. Revenue FY2022 408.3M HKD. Revenue FY2023 271.33M HKD. Revenue FY2024 317.11M HKD. Revenue FY2025 353.78M HKD. Operating income FY2021 114.01M HKD. Operating income FY2022 139.61M HKD. Operating income FY2023 116.95M HKD. Operating income FY2024 64.15M HKD. Operating income FY2025 63.72M HKD. Net income FY2021 98.94M HKD. Net income FY2022 126.15M HKD. Net income FY2023 64.19M HKD. Net income FY2024 21.88M HKD. Net income FY2025 34.22M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue353.78M HKD317.11M HKD271.33M HKD408.3M HKD320.34M HKD
Cost of goods sold238.66M HKD20.27M HKD136.13M HKD222.87M HKD176.59M HKD
Gross profit115.12M HKD296.85M HKD135.21M HKD185.43M HKD143.75M HKD
Selling, general, and administrative51.4M HKD2.1M HKD18.25M HKD45.82M HKD29.74M HKD
Operating expenses51.4M HKD232.7M HKD18.25M HKD45.82M HKD29.74M HKD
Interest income—902K HKD3.71M HKD255K HKD105K HKD
Interest expense9.78M HKD15.58M HKD12.07M HKD8.79M HKD7.94M HKD
Depreciation and amortization56.81M HKD49.28M HKD47.64M HKD44.64M HKD36.57M HKD
Operating income63.72M HKD64.15M HKD116.95M HKD139.61M HKD114.01M HKD
Net income34.22M HKD21.88M HKD64.19M HKD126.15M HKD98.94M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.01

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.110.070.040.01Q4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24Q4 '24Q2 '26
Q4 2021, reported Nov 26, 2021: actual 0.044, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 26, 2022: actual 0.055, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 15, 2022: actual 0.057, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 23, 2023: actual 0.069, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 30, 2023: actual 0.02, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 25, 2024: actual 0.044, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 25, 2024: actual 0.026, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 29, 2026: actual 0.007, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates216.61M186.68M156.75M126.83MQ4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24Q4 '24Q2 '26
Q4 2021, reported Nov 26, 2021: actual 150.28M HKD, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 26, 2022: actual 170.06M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 15, 2022: actual 208.28M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 23, 2023: actual 200.02M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 30, 2023: actual 135.16M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 25, 2024: actual 136.18M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 25, 2024: actual 147.97M HKD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 29, 2026: actual 179.53M HKD, estimate —, surprise —, Comparison unavailable.

2189.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

Continue in GoAI

Research 2189.HK

research.disclaimer